|
|
Line 10: |
Line 10: |
|
| |
|
| {{Template:SUIT text D011}} | | {{Template:SUIT text D011}} |
| SUIT-005 O2 pfi D011 protocols provide information on the [[Fatty_acid_oxidation_pathway_control_state|F-pathway]], the combined [[FN|FN]] pathway, and the convergence [[FNS |FNS]] pathways in the [[Oxidative phosphorylation|OXPHOS state]]. [[FNS |FNS]] comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum [[OXPHOS-capacity| OXPHOS-]] and [[ET-capacity |ET-capacity]]. SUIT-005 can be extended with the CIV assay module.
| |
| This protocol is linked to [[SUIT-002 O2 pfi D006]] - SUIT RP2, specifically for human skeletal muscle mitochondria. SUIT-005 O2 pfi D011 is harmonized with [[SUIT-004 O2 pfi D010]].
| |
| The F-pathway has to be tested previously.
| |
|
| |
|
| |
|
| __TOC__ | | __TOC__ |
Revision as of 15:53, 19 July 2019
- high-resolution terminology - matching measurements at high-resolution
SUIT-005 O2 pfi D011
Description
Abbreviation: RP2-short pfi
Reference: A: - SUIT-005
SUIT number: D011_1OctM;2D;3P;4S;5U;6Rot;7Ama;8AsTm;9Azd
O2k-Application: O2
- MitoPedia: SUIT short protocol linked to SUIT-002 O2 pfi D006 - SUIT RP2 (human skeletal muscle)
- SUIT protocol pattern: 1OctM;2D;3P;4S;5U;6Rot
SUIT-005 O2 pfi D011 protocol provides information on the F-pathway, the combined FN pathway, and the convergence FNS pathways in the OXPHOS state. FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET capacity. SUIT-005 can be extended with the CIV assay module.
This protocol is linked to SUIT-002 O2 pfi D006 - SUIT RP2, specifically for human skeletal muscle mitochondria. SUIT-005 O2 pfi D011 is harmonized with SUIT-004 O2 pfi D010.
The F-pathway has to be tested previously.
Communicated by Doerrier C, Iglesias-Gonzalez J and Gnaiger E (last update 2019-06-05)
Steps and respiratory states
Step
|
State
|
Pathway
|
Q-junction
|
Comment - Events (E) and Marks (M)
|
1OctM
|
OctML(n)
|
F(N)
|
FAO
|
1OctM
- Respiratory stimulation of the FAO-pathway, F, by fatty acid FA in the presence of malate M. Malate is a type N substrate (N), required for the F-pathway. In the presence of anaplerotic pathways (e.g., mitochondrial malic enzyme, mtME) the F-pathway capacity is overestimated, if there is an added contribution of NADH-linked respiration, F(N) (see SUIT-002). The FA concentration has to be optimized to saturate the FAO-pathway, without inhibiting or uncoupling respiration.
- Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
- Non-phosphorylating resting state (LEAK state); LEAK respiration L(n) in the absence of ADP, ATP, AMP (no adenylates).
|
2D
|
OctMP
|
F(N)
|
FAO
|
1OCtM;2D
- Respiratory stimulation of the FAO-pathway, F, by fatty acid FA in the presence of malate M. Malate is a type N substrate (N), required for the F-pathway. In the presence of anaplerotic pathways (e.g., mitochondrial malic enzyme, mtME) the F-pathway capacity is overestimated, if there is an added contribution of NADH-linked respiration, F(N) (see SUIT-002). The FA concentration has to be optimized to saturate the FAO-pathway, without inhibiting or uncoupling respiration.
- Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
- OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
|
2c
|
OctMcP
|
F(N)
|
FAO
|
1OCtM;2D;2c
- Respiratory stimulation of the FAO-pathway, F, by fatty acid FA in the presence of malate M. Malate is a type N substrate (N), required for the F-pathway. In the presence of anaplerotic pathways (e.g., mitochondrial malic enzyme, mtME) the F-pathway capacity is overestimated, if there is an added contribution of NADH-linked respiration, F(N) (see SUIT-002). The FA concentration has to be optimized to saturate the FAO-pathway, without inhibiting or uncoupling respiration.
- Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
- Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).
- OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
|
3P
|
OctPMP
|
FN
|
F&CI
|
1OctM;2D;2c;3P
- Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
- OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
|
4S
|
OctPMSP
|
FNS
|
F&CI&II
|
1OctM;2D;2c;3P;4S
- Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F.
- OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
|
5U
|
OctPMSE
|
FNS
|
F&CI&II
|
1OctM;2D;2c;3P;4S;5U
|
6Rot
|
SE
|
S
|
CII
|
1OctM;2D;3P;4S;5U;6Rot
|
7Ama
|
ROX
|
|
|
1OctM;2D;3P;4S;5U;6Rot;7Ama
- Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
|
Step
|
Respiratory state
|
Pathway control
|
ET-Complex
|
Comment
|
## AsTm
|
AsTmE
|
CIV
|
CIV
|
|
## Azd
|
CHB
|
|
|
|
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- ยป Coupling control state
- ยป ET capacity
- ยป OXPHOS capacity
- ยป LEAK respiration
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Glossary
- ยป List of SUIT states
- ยป SUIT concept
Strengths and limitations
- + The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
- + FNS OXPHOS-capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + FNS ET-capacity is a good estimate of overall ET-capacity in many cell types.
- + The presence of PM and S establishes a fully operative TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- + Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- - F- OXPHOS-capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
- SUIT-002: A comparable but more comprehensive protocol comprising additional substrate states.
- SUIT-002 O2 pfi D006: A comparable but more comprehensive pfi-specific protocol comprising additional substrate states.
- imt, ROX: 1OctM;2D;2c;3P;4S;5U;6Rot;7Ama
- pfi, high O2, no ROX: FNS(PM)01_pfiO2,1OctM,2D(c),3P,4S,5U,6Rot
References
MitoPedia concepts:
SUIT protocol,
SUIT A,
Find
MitoPedia methods:
Respirometry
Cookies help us deliver our services. By using our services, you agree to our use of cookies.